Anebulo Pharmaceuticals, Inc.
ANEB
$1.14
$0.065.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.25M | 4.58M | 4.76M | 4.96M | 5.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.01M | 8.18M | 8.31M | 9.46M | 10.66M |
| Operating Income | -8.01M | -8.18M | -8.31M | -9.46M | -10.66M |
| Income Before Tax | -7.67M | -7.92M | -8.20M | -9.35M | -10.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.67 | -7.92 | -8.20 | -9.35 | -10.49 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.67M | -7.92M | -8.20M | -9.35M | -10.49M |
| EBIT | -8.01M | -8.18M | -8.31M | -9.46M | -10.66M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.29 | -0.31 | -0.32 | -0.36 | -0.41 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.20 | -0.23 | -0.26 |
| EPS Diluted | -0.29 | -0.31 | -0.32 | -0.36 | -0.41 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.20 | -0.23 | -0.26 |
| Average Basic Shares Outstanding | 105.22M | 103.59M | 103.29M | 102.99M | 102.69M |
| Average Diluted Shares Outstanding | 105.22M | 103.59M | 103.29M | 102.99M | 102.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |